Bringing The Fight To Dementia & Autism
Pioneering Breakthroughs In Brain Health
We are on a relentless pursuit to improve the lives of millions suffering from dementia, autism and other cognitive conditions and their carers. Our ground-breaking treatment candidates, DL33 and MO8, stand at the forefront of this revolution, offering the potential for a healthier future.
A New Horizon in Dementia Treatment and Autism Care
DL33 and MO8 are breakthrough potential therapies backed by cutting-edge research and scientific evidence.
DL33 reverses the cognitive decline in mouse models of Alzheimer’s disease and Childhood dementia.
MO8 is a potential breakthrough therapy backed by research and scientific evidence.
DL33 and M08 are pioneering treatments aimed at and addressing neurological conditions like dementia and autism. They offer new hope for improving quality of life and advancing neurological care.
“To make a difference, you must be different.” By leading with cutting-edge science and a global vision, Meizon strives to maximize health outcomes for society.
Originating from Florey Institute of Neuroscience and Mental Health, a leading Neuroscience Institute, and the University of Melbourne, DL33 and MO8 are poised to address disease states with unmet clinical needs, while make a global impact on brain health.
Together we are bringing hope and aim to provide relief to millions around the world.
Investing in Meizon Innovation is investing in the future of healthcare. We are at a pivotal moment, moving towards clinical trials for DL33 and MO8 and we need your support to make this vision a reality.
Copyrights @ meizon 2024 Reserved
Copyrights @ meizon 2024 Reserved
Website by Avanttech
